Cargando…
Secondary prevention of rheumatic heart disease in Ethiopia: a multicenter study
BACKGROUND: Ethiopia has a high acute rheumatic fever (ARF) and rheumatic heart disease (RHD) prevalence, and to our knowledge, there are no data on the status of secondary prevention in children with RHD. This study describes the status of secondary RHD prevention. METHODS: A multicenter, prospecti...
Autores principales: | , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8809239/ https://www.ncbi.nlm.nih.gov/pubmed/35109807 http://dx.doi.org/10.1186/s12872-022-02473-4 |
_version_ | 1784643983888089088 |
---|---|
author | Belay, Wubishet Dessie, Azene Ahmed, Hayat Gedlu, Etsegenet Mariyo, Abinet Shehibo, Abdulkadir Tigabu, Zemene Aliyu, Muktar H. Soslow, Jonathan |
author_facet | Belay, Wubishet Dessie, Azene Ahmed, Hayat Gedlu, Etsegenet Mariyo, Abinet Shehibo, Abdulkadir Tigabu, Zemene Aliyu, Muktar H. Soslow, Jonathan |
author_sort | Belay, Wubishet |
collection | PubMed |
description | BACKGROUND: Ethiopia has a high acute rheumatic fever (ARF) and rheumatic heart disease (RHD) prevalence, and to our knowledge, there are no data on the status of secondary prevention in children with RHD. This study describes the status of secondary RHD prevention. METHODS: A multicenter, prospective study was performed on children aged 5–17 years with RHD in Ethiopia. Good adherence was defined as at least 80% completion of benzathine penicillin (BPG) or oral Amoxicillin within the previous year. The primary outcome measure was adherence to prophylaxis, expressed as a proportion. Socio-demographics, severity of RHD, and ARF recurrence were evaluated. RESULTS: A total of 337 children with a mean age of 12.9 ± 2.6 years were included. The majority (73%) had severe aortic/mitral disease. Participants were on BPG (80%) or Amoxicillin (20%) prophylaxis. Female sex (P = 0.04) use of BPG (0.03) and shorter mean duration of prophylaxis in months (48.5 ± 31.5 vs. 60.7 ± 33, respectively, P < 0.008) predicted good adherence. Running out of medications (35%), interrupted follow-up (27%), and the COVID-19 pandemic (26%) were the most common reasons for missing prophylaxis. Recurrence of ARF was higher in participants on Amoxicillin compared with BPG (40% vs. 16%, P < 0.001) and in those with poor adherence compared with good adherence (36.8% vs. 17.9%, respectively, P = 0.005). Type and duration of prophylaxis (OR 0.5, CI = 0.24, 0.9, P = 0.02; OR = 1.1, CI = 1.1, 1.2, P = 0.04, respectively), and sex (OR = 1.9, CI = 1.1, 3.4, P = 0.03) were independent predictors of poor adherence. CONCLUSION: Poor adherence is prevalent in Ethiopian children living with RHD. Amoxicillin is a suboptimal option for prophylaxis as its use is associated with lower adherence and a higher rate of ARF recurrence. SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1186/s12872-022-02473-4. |
format | Online Article Text |
id | pubmed-8809239 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2022 |
publisher | BioMed Central |
record_format | MEDLINE/PubMed |
spelling | pubmed-88092392022-02-02 Secondary prevention of rheumatic heart disease in Ethiopia: a multicenter study Belay, Wubishet Dessie, Azene Ahmed, Hayat Gedlu, Etsegenet Mariyo, Abinet Shehibo, Abdulkadir Tigabu, Zemene Aliyu, Muktar H. Soslow, Jonathan BMC Cardiovasc Disord Research BACKGROUND: Ethiopia has a high acute rheumatic fever (ARF) and rheumatic heart disease (RHD) prevalence, and to our knowledge, there are no data on the status of secondary prevention in children with RHD. This study describes the status of secondary RHD prevention. METHODS: A multicenter, prospective study was performed on children aged 5–17 years with RHD in Ethiopia. Good adherence was defined as at least 80% completion of benzathine penicillin (BPG) or oral Amoxicillin within the previous year. The primary outcome measure was adherence to prophylaxis, expressed as a proportion. Socio-demographics, severity of RHD, and ARF recurrence were evaluated. RESULTS: A total of 337 children with a mean age of 12.9 ± 2.6 years were included. The majority (73%) had severe aortic/mitral disease. Participants were on BPG (80%) or Amoxicillin (20%) prophylaxis. Female sex (P = 0.04) use of BPG (0.03) and shorter mean duration of prophylaxis in months (48.5 ± 31.5 vs. 60.7 ± 33, respectively, P < 0.008) predicted good adherence. Running out of medications (35%), interrupted follow-up (27%), and the COVID-19 pandemic (26%) were the most common reasons for missing prophylaxis. Recurrence of ARF was higher in participants on Amoxicillin compared with BPG (40% vs. 16%, P < 0.001) and in those with poor adherence compared with good adherence (36.8% vs. 17.9%, respectively, P = 0.005). Type and duration of prophylaxis (OR 0.5, CI = 0.24, 0.9, P = 0.02; OR = 1.1, CI = 1.1, 1.2, P = 0.04, respectively), and sex (OR = 1.9, CI = 1.1, 3.4, P = 0.03) were independent predictors of poor adherence. CONCLUSION: Poor adherence is prevalent in Ethiopian children living with RHD. Amoxicillin is a suboptimal option for prophylaxis as its use is associated with lower adherence and a higher rate of ARF recurrence. SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1186/s12872-022-02473-4. BioMed Central 2022-02-02 /pmc/articles/PMC8809239/ /pubmed/35109807 http://dx.doi.org/10.1186/s12872-022-02473-4 Text en © The Author(s) 2022 https://creativecommons.org/licenses/by/4.0/Open AccessThis article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) . The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/ (https://creativecommons.org/publicdomain/zero/1.0/) ) applies to the data made available in this article, unless otherwise stated in a credit line to the data. |
spellingShingle | Research Belay, Wubishet Dessie, Azene Ahmed, Hayat Gedlu, Etsegenet Mariyo, Abinet Shehibo, Abdulkadir Tigabu, Zemene Aliyu, Muktar H. Soslow, Jonathan Secondary prevention of rheumatic heart disease in Ethiopia: a multicenter study |
title | Secondary prevention of rheumatic heart disease in Ethiopia: a multicenter study |
title_full | Secondary prevention of rheumatic heart disease in Ethiopia: a multicenter study |
title_fullStr | Secondary prevention of rheumatic heart disease in Ethiopia: a multicenter study |
title_full_unstemmed | Secondary prevention of rheumatic heart disease in Ethiopia: a multicenter study |
title_short | Secondary prevention of rheumatic heart disease in Ethiopia: a multicenter study |
title_sort | secondary prevention of rheumatic heart disease in ethiopia: a multicenter study |
topic | Research |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8809239/ https://www.ncbi.nlm.nih.gov/pubmed/35109807 http://dx.doi.org/10.1186/s12872-022-02473-4 |
work_keys_str_mv | AT belaywubishet secondarypreventionofrheumaticheartdiseaseinethiopiaamulticenterstudy AT dessieazene secondarypreventionofrheumaticheartdiseaseinethiopiaamulticenterstudy AT ahmedhayat secondarypreventionofrheumaticheartdiseaseinethiopiaamulticenterstudy AT gedluetsegenet secondarypreventionofrheumaticheartdiseaseinethiopiaamulticenterstudy AT mariyoabinet secondarypreventionofrheumaticheartdiseaseinethiopiaamulticenterstudy AT shehiboabdulkadir secondarypreventionofrheumaticheartdiseaseinethiopiaamulticenterstudy AT tigabuzemene secondarypreventionofrheumaticheartdiseaseinethiopiaamulticenterstudy AT aliyumuktarh secondarypreventionofrheumaticheartdiseaseinethiopiaamulticenterstudy AT soslowjonathan secondarypreventionofrheumaticheartdiseaseinethiopiaamulticenterstudy |